and everyone, joining for you, us afternoon, thank Mike. Good Thank you, today.
On trials. financial my with on then line discussions update collaboration the open results, an appreciate this up agreements, questions. on a the As on discussion of we'll our Vicky recent product FACT-X particularly update support and like fourth our clinical Celcuity. of ongoing comments call, and projects and our always, we status I'd quarter focus for to your the of we'll continued of our FACT-X follow you results, will development collaboration and
most underlying that CELsignia therapy can capability most potentially we Celcuity's matching molecular and identifies third-generation pathway dysregulated prescribed. proprietary in the of test so to Since is tumor, a the for thus, are to CELsignia in create characterize can strategy. signaling the be complex the our cellular patient's dysregulated platform platform, business efficacious leverage activity, diagnostic too signaling cases, targeted
to targeted treat new our able a companies targeted pharmaceutical obtain to to goal, is therapies tests would goal To evaluate these pathway first realizing help to therapies are their their of CELsignia the efficacy we the the successful, step with indication for for this new indications Our the market evaluated CELsignia identify. collaborate obtaining critical expands patients, patient targeted take a companies towards test. pharmaceutical represent populations collaborations by If in that us towards selected step activity therapies. uniquely
therapeutic is We believe need for HERX-negative breast for options patients. a cancer significant unmet there new
disease undiagnosed untreated mechanism. XX% these research have Our believe of the can patients for them. CELsignia patients these that an targeted and test the many We benefit most XX% likely identify to of therapy, to and mechanism our disease suggests roughly
December, collaboration. with Our Biotech we and momentum. to we announcement for clinical trial Hospital and the announced announced Puma's of in another Faslodex. drug trial We and of trial a Nerlynx and January drug followed Phase evaluate late the this II safety clinical for Astrazeneca's efficacy the collaboration this announcement Puma have are efforts And In just area collaboration our third General in months, collaborations. past in Massachusetts fourth with the gaining X
despite pan-HER The the XALKORI, COVID-XX. c-Met inhibitor efficacy trial II a and the from Pfizer most these Cannon evaluate and We're and proud X that headwinds Pfizer targeted Phase Research therapies, for collaboration Institute to VIZIMPRO, a is safety will of Sarah finalized inhibitor. recent have and with advanced agreements
of new trials breast HERX-negative first drug of pathological test, obtain our response patients is each our breast a trials HERX treatments of to therapies activity the late-stage by identified are The than care X pathway complete higher evaluating rate patients. to anti-HERX and FACT-X demonstrate current FACT-X of neoadjuvant trials standard will to early-stage anti-HERX chemotherapies. the cancer goal CELsignia from metastatic new study be these these in Now collaboration cancer Both patients.
to many who CELsignia treatment patients receive can Some are We're recur. significant their a patients. extending to play pathological a cancer the in have complete likely hopeful neoadjuvant lives response drug cancer our less test role of breast
equally to some patients coming about expect We're or collaboration we we'll the that additional HERX months. work either the c-Met close evaluate to be hyperactive HERX the with agreements progress, in research and centers. collaborations excited new will prominent hyperactive we're and tumors and new of signaling The with the in discussions able we opportunity soon have We're tumors. announce our cancer to excited most hopeful collaborations signaling about
with don't pharmaceutical we Since breast hyperactive those discussions with discussions collaborations evaluate to mid-XXXX PIXK companies with signaling inhibitors also until progressing. these in close ovarian and hyperactive Our c-Met or at are HERX expect patients patients beyond. to in signaling, sometime PIXK an earlier and cancer involving those stage or are
with disease the test to respected will to leaders their and for believe reflects thought we looking the the collaborate the our oncology their We're having their drivers be unique clinical They're conducting respect country, patients. undiagnosed offers most that identify forward and amongst CELsignia for these investigators the interest potential in with us opportunity new to researchers trials. collaborating in
we test. quarter, to activity advance the development of additional continued pathway During CELsignia
significant cancer. which molecular RAS goal to pharmaceutical Our in that many all this in cancers, identify is and companies to involved with nodes driven led tests ovarian of develop in research tests breast sponsor for area. RAS undetectable network regulated has is signaling pathway cancers, CELsignia This new a percentage responsible
second report at quarter conference tests a expect We for of new cancer to the in data XXXX. these
a can the efficacy as resistance to therapy. in inhibits Our activate CELsignia the at the unique a pathway, platform and also is RAS many targeted therapy which of RAS targeted various may mechanism, pathway, In present, typically pathway that RAS the into insights provides X interdependence is turn, another of this pathways. referred reduce
it's we interactions these PIXK generally using inhibition cells. the of between versa pathways, patient's patients. mTOR the activate understood different signaling analyze network instance, vice that and can a can detrimentally this With tumor interconnected in some For CELsignia,
Therefore, would can the prevent it blockade to drug better occurring. ultimately, for and from be patient that these The survival. interactions benefit resistance the us tumor allows combinations identify overall mechanisms control longer and
the activities. In us the also pathways different superiority nodes. approved relative the And the assess targeting relative addition, to collaboration guide RAS investigational this and which we can targeted RAS efficacy of therapies of potency for and our enables therapies different characterize helps
on trials. update active Finally, you to I'd our X like
trial hospitalizations to as as mid-November. in in may This increasing but began As quite general not you similar activities impacted is be aware, rapidly occurred clinical earlier what in year, severe. COVID-XX the
clinical weeks few resumed Since the related COVID-XX have more of generally trial peaked to appear hospitalizations activities number broadly. a ago,
to XXXX. expect or all hard We results interim rollout our COVID-XX related as clinical this aware, the hopeful future of recent late vaccines, last. in the impacts from it's the delays bout most we're early of And and with trials. on XXXX you're COVID-XX FACT-X FACT-X predict trials But is
now review results. Vicky I'd That to like concludes my initial to turn to our financial it remarks. over
